Navigation Links
Tomophase Announces First Sale of Its OCT Imaging System (OCTIS™) for Research Use to the University of Texas
Date:4/11/2011

BURLINGTON, Mass., April 11, 2011 /PRNewswire/ -- Tomophase Corporation, a leading developer of minimally invasive optical coherence tomography (OCT) tissue imaging devices, announced today that it has installed the first of its OCT Imaging Systems (OCTIS™) at the University of Texas Medical Branch (UTMB) in Galveston, Texas.

This first system sale will be for research use in the laboratory of Dr. Massoud Motamedi, Director, Center for Biomedical Engineering at UTMB. Dr. Motamedi will be conducting research on application of OCT in intraluminal imaging.

Dr Motamedi said, "There is a great need for the development of a high resolution image-based technique for non-invasive assessment of tissue morphology within the intraluminal space in order to assess changes that may occur in tissue morphology in response to therapeutic interventions or disease progression. The Tomophase OCT system provides the capabilities that are needed to rapidly acquire high-resolution OCT images in the lung, colon and GI tract in human and in various animal models. This imaging system could provide details about tissue morphology and structure that could potentially significantly improve early detection of diseases such as epithelial neoplasm as well as assessment of epithelial integrity and treatment safety and efficacy."

"We are pleased that our state-of-the-art OCT tissue imaging system meets the needs of the University of Texas. High resolution tissue imaging is the focus of our efforts at Tomophase," said Ralph Johnston, President, and COO.

"Our company is committed to providing new, innovative tissue imaging systems to improve the management of pulmonary disease. It is gratifying to see a group such as UTMB, with so much experience in Interventional Pulmonology imaging, choose our OCTIS system," said Peter Norris, PhD CEO.

About UTMB Biomedical Engineering

Established in 1891, Texas' academic health center comprises four health sciences schools, three institutes for advanced study, a research enterprise that includes one of only two national laboratories dedicated to the safe study of infectious threats to human health, and a health system offering a full range of primary and specialized medical services throughout Galveston County and the Texas Gulf Coast region. UTMB is a component of the University of Texas System and a member of the Texas Medical Center.

About Tomophase

Tomophase Corporation is a privately held opto-medical device company with a proprietary position in real-time, high-resolution, cross-sectional tissue imaging using a variant of OCT. Our goal is to provide physicians with heretofore unobtainable airway microstructural images to improve the management and clinical outcome of pulmonary disease. Examples of our tissue imaging results are available at http://www.tomophase.com.

For further information:

Dr. Peter Norris, CEO
Tomophase Corporation
P: (781) 229-5700
E: pnorris@tomophase.com

Ralph Johnston, President, COO
Tomophase Corporation
P: (781) 229-5700
E: rjohnston@tomophase.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Tomophase Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tomophase Receives Qualifying Therapeutic Discovery Project (QTDP) Award
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... After spending the past two years building a state-of-the-art technology which ... offers this platform to healthcare stakeholders (hospitals, foundations, biopharma companies etc.) ... collection vis a vis their members, under their own brand. Three ... offer. ... ...
(Date:8/15/2017)... ... August 15, 2017 , ... Any expert in stem cell research ... disciplines for more than half a century. Despite their essential roles in human ... widely known that molecular tags developed for this purpose also tag other, more abundant, ...
(Date:8/15/2017)... , ... August 15, 2017 , ... ... shopping cart. Now mobile responsive, the new website makes it easy to navigate ... in between. Users can now find detailed product information, educational industry content and ...
(Date:8/11/2017)... 2017  Market researcher Kalorama Information was ... regarding the telemedicine market.  The telemedicine market ...  The article, "Heart and Asthma Monitors? ... information from Kalorama Information,s Remote Patient Monitoring ...  (Sleep, Diabetes, Vital Signs /EKG and ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):